United Therapeutics lung drug gets FDA nod, shares rise

According to Esha Day of Reuters, United Therapeutics Corp (UTHR.O) said U.S. health regulators approved its inhaled drug to treat pulmonary hypertension, sending its shares up as much as 13 percent.

The Food and Drug Administration approved Tyvaso inhalation solution for the treatment of pulmonary arterial hypertension (PAH) using the Tyvaso inhalation system, the company said.

Even though the drug, Tyvaso, had faced a couple of delays on its way to approval, analysts were expecting a regulatory nod by Thursday's action date as it was mostly the drug's delivery device that had faced a close scrutiny than the drug itself.

Another win for biopharma? We'd like to hear your thoughts.


Join us on Twitter!

This is the global drug delivery partnerships meeting place, focusing on bringing together professionals seeking the latest strategies, industry updates, and networking opportunities to help position your company for a successful partnership/collaboration. Join us today!

Share this article with your social network, just click below to share now!

Share |